Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial-Reference-Cited by-同舟云学术

Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial

Published:2017-06-22 Issue:25 Volume:129 Page:3314-3321
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Uffmann Madita¹,Rasche Mareike²,Zimmermann Martin¹,von Neuhoff Christine²,Creutzig Ursula¹,Dworzak Michael³,Scheffers Lenie⁴,Hasle Henrik⁵,Zwaan C. Michel⁴⁶,Reinhardt Dirk²,Klusmann Jan-Henning¹^ORCID

Affiliation:

1. Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany;

2. Pediatric Hematology and Oncology, Pediatrics III, Essen University Hospital, Essen, Germany;

3. Department of Pediatrics, St. Anna Children's Hospital/Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria;

4. Dutch Childhood Oncology Group, The Hague, The Netherlands;

5. Department of Pediatrics, Aarhus University Hospital, Skejby, Denmark; and

6. Department of Pediatric Oncology/Hematology, Erasmus Medical Center/Sophia Children’s Hospital, Rotterdam, The Netherlands

Abstract

Key Points Reducing therapy intensity in the ML-DS 2006 trial did not impair the excellent prognosis in ML-DS compared with the historical control. Early treatment response and gain of chromosome 8 are independent prognostic factors.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/25/3314/1364442/blood765057.pdf

Reference37 articles.

1. Pattern of malignant disorders in individuals with Down’s syndrome;Hasle;Lancet Oncol,2001

2. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes;Vardiman;Blood,2009

3. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group;Bennett;Ann Intern Med,1985

4. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts;Langebrake;Klin Padiatr,2005

5. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome;Klusmann;Blood,2008

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival outcomes of myeloid leukemia associated with Down syndrome and de novo acute myeloid leukemia in children: Experience from a single tertiary center in Thailand;Pediatric Hematology and Oncology;2023-11-27

2. Down syndrome and leukemia: An insight into the disease biology and current treatment options;Blood Reviews;2023-11

3. Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome;Blood Advances;2023-10-27

4. Management of Down Syndrome–Associated Leukemias;JAMA Oncology;2023-09-01

5. Down syndrome and leukemia: from basic mechanisms to clinical advances;Haematologica;2023-07-13